ERASCA INC (ERAS)
Health Care · Precision oncology / RAS pathway therapeutics · NASDAQ
A precision oncology company developing first-in-class RAS/MAPK pathway-targeting therapies for cancers driven by the most frequently mutated oncogene affecting millions of patients annually.
What ERASCA INC does
Erasca is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies targeting RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs—ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor—plus a discovery-stage EGFR biparatopic antibody program. Erasca pursues a modality-agnostic strategy using small and large molecule therapeutics to systematically target multiple nodes within the RAS/MAPK pathway to address cancers with high unmet medical needs.
Themes: ["precision oncology"]
Fundamentals
- Price$19.18 as of 2026-07-09 close
- Market cap$6.0B as of 2026-07-10
- 1-year return+1192.5% as of 2026-07-09 close
- ROE-77.0% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.67 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: ERAS-0015 and ERAS-4001 are in clinical stages with uncertain efficacy and safety profiles; failure to demonstrate sufficient clinical benefit could halt development and render the pipeline non-viable."]
Competitors & peers
- Array BioPharma
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.